6-K 1 nymox_6k.htm FORM 6-K nymox_6k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of May, 2025

 

Commission File Number: 001-12033

 

 Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

 

Bay & Deveaux Streets, Nassau, The Bahamas 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40‑F.

 

Form 20-F ☒    Form 40-F ☐

 

 

 

 

Nymox Pharmaceutical Corporation (the “Company”) has been made aware that 2 individuals formerly affiliated with the Company have filed complaints against it, alleging various claims associated with their termination for cause. These individuals are 2 of the same plaintiffs awaiting their court ordered requirement to pay the Company substantial legal fees and damages after they lost on their request for an injunction against the Company.  The Company believes the claims are without merit and intends to defend against them.

 

 
2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 22, 2025

 

NYMOX PHARMACEUTICAL CORPORATION

 

 

 

 

By:

 /s/ Paul Averback

 

 

Name:

Paul Averback

 

Title:

President and Chief Executive Officer

 

 
3